POLQ — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3633764	0.53	13/20
SCHEMBL3741058	0.61	12/20
SCHEMBL272016	0.49	10/20
SCHEMBL1993639	0.49	10/20
SCHEMBL3278364	0.48	10/20
SCHEMBL2261115	0.39	9/20
SCHEMBL1892783	0.55	8/20
SCHEMBL2307624	0.54	8/20
SCHEMBL1312888	0.51	8/20
SCHEMBL1312890	0.51	8/20
SCHEMBL2664649	0.51	8/20
SCHEMBL1006501	1.00	7/20
SCHEMBL654170	0.50	7/20
SCHEMBL3871929	0.58	5/20
SCHEMBL2754135	0.54	5/20
SCHEMBL3944077	0.43	5/20
SCHEMBL3431736	0.42	5/20
SCHEMBL3577293	0.51	4/20
SCHEMBL3391553	0.51	4/20
SCHEMBL967785	0.50	4/20

Clinical trials — most relevant to POLQ by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PREventing Progression of Adipose Tissue Redistribution	PHASE4	COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Danazol for Treatment of Cytopenias in Patients With Cirrhosis	PHASE2	RECRUITING
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Cohort of Tumors With POLE/D1 Mutation	nan	RECRUITING
The Periodontal Disease and Diabetes Mellitus Interrelationship Among Adult Malaysians	nan	COMPLETED
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification	nan	RECRUITING
Causes of Rotavirus Vaccine Failure in Zambian Children	nan	COMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Implementation of Molecular Diagnostic Pathways	nan	UNKNOWN
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer	nan	NOT_YET_RECRUITING
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome)	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens.	nan	NOT_YET_RECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a POLQ binder may also engage these)

Protein	Name	Similarity
Q8CGS6	—	1.000	Q8CGS6 →
B6DMK2	—	0.997	B6DMK2 →
Q2VPA6	—	0.996	Q2VPA6 →
Q69LX2	—	0.995	Q69LX2 →
A2RUV5	—	0.995	A2RUV5 →
Q10HL3	—	0.995	Q10HL3 →
O18475	—	0.994	O18475 →
O09053	—	0.994	O09053 →
D3Z4R1	—	0.993	D3Z4R1 →
Q5RF63	—	0.992	Q5RF63 →
O93530	—	0.992	O93530 →
WRN	Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN	0.992	landscape →
P84634	—	0.992	P84634 →
RECQL	ATP-dependent DNA helicase Q1	0.992	landscape →
Q96BT7	—	0.992	Q96BT7 →
RAD54L	DNA repair and recombination protein RAD54-like	0.992	landscape →
Q9SP32	—	0.992	Q9SP32 →
Q9CXF7	—	0.991	Q9CXF7 →
Q8TDG4	—	0.991	Q8TDG4 →
Q5R746	—	0.991	Q5R746 →
A2PYH4	—	0.991	A2PYH4 →
Q95K79	—	0.991	Q95K79 →
Q5D892	—	0.991	Q5D892 →
Q8GT06	—	0.990	Q8GT06 →
Q7ZU90	—	0.990	Q7ZU90 →
Q6AYJ1	—	0.990	Q6AYJ1 →
Q1DKI1	—	0.990	Q1DKI1 →
Q80Y20	—	0.990	Q80Y20 →
Q8NDG6	—	0.990	Q8NDG6 →
Q99741	—	0.989	Q99741 →